As part of our ongoing aim to bring you reports of innovative developments, we have added a review of the recent Titan study which explores apalutamide use plus androgen-deprivation therapy in patients with metastatic castration-sensitive prostate cancer.
Independent commentary is provided by Dr Laurence Krieger, Consultant General Physician and undergraduate trainee supervisor for the Royal College of Physicians at Royal North Shore Hospital, Sydney.
Please login below to download this issue (PDF)